Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. (DXCM) is widely described in its own communications as a global leader in glucose biosensing and real-time continuous glucose monitoring (CGM) for people with diabetes. The Dexcom news stream features regular updates on product launches, clinical evidence, coverage decisions, financial performance, and leadership developments, all centered on its CGM and biosensing technology.
Investors and healthcare observers following DXCM news will find detailed announcements on new products such as the Dexcom G7 15 Day CGM System, which is designed to provide real-time glucose readings over extended wear, and Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using long-acting insulin. News items also cover enhancements to the Stelo app for metabolic health, AI-enabled features like meal logging, and integrations with connected devices and insulin delivery systems.
Dexcom’s news releases highlight clinical and real-world data presented at major conferences, including the European Association for the Study of Diabetes (EASD), where the company shares findings on outcomes such as pregnancy complications, diabetic ketoacidosis management, and cost-effectiveness of CGM compared to fingersticks. Coverage and reimbursement milestones, such as expanded access under the Régie de l’assurance maladie du Québec (RAMQ) and other public programs, are also frequent topics.
Financial results and guidance updates, leadership transitions, and board appointments are reported through earnings releases and Form 8-K related press announcements. For anyone tracking how CGM technology, biosensing, and digital health tools are evolving in diabetes and metabolic health, the Dexcom news page offers an ongoing record of the company’s product, clinical, and corporate developments. Bookmark this page to follow the latest DXCM press releases and regulatory disclosures as they are issued.
Dexcom, Inc. (NASDAQ: DXCM) has launched a new Digital Diabetes Care Program in partnership with Green Shield and The Health Depot. This initiative will provide Green Shield plan members access to the Dexcom G6 real-time continuous glucose monitoring (rtCGM) system along with virtual diabetes management support. Benefits include automated product shipments, preferred pricing, direct billing, and co-payment assistance for Dexcom supplies. The program aims to enhance diabetes management and improve health outcomes by providing personalized support and clinical consultations.
Dexcom G7 has received FDA clearance for all diabetes types in individuals aged two and older. This next-generation continuous glucose monitoring (CGM) system boasts an overall MARD of 8.2%, making it the most accurate FDA-cleared CGM. With a 60% smaller, all-in-one wearable design, it offers a 30-minute sensor warmup and a suite of features including real-time connectivity with wearables and an upgraded mobile app. Furthermore, Dexcom's G7 is the number one covered CGM, with many users incurring low out-of-pocket costs.
Dexcom, Inc. (NASDAQ: DXCM) announces its participation in the Truckers’ Health Adaptive Technology (T.H.A.T.) project to enhance health outcomes for professional truck drivers during National Diabetes Awareness Month. This initiative utilizes real-time continuous glucose monitoring via Dexcom G6 systems, integrating health data to provide personalized virtual care. The T.H.A.T. project will track health metrics of 200 truck drivers and aims to address their higher diabetes risk. This innovative model may be expanded to other high-risk workforces in Canada.
DexCom, Inc. (NASDAQ:DXCM) announced that Matt Dolan, Executive Vice President of Strategy, Corporate Development, and DexCom Labs, will present at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 8:30 am (EST). The presentation will provide updates about the company and its innovative continuous glucose monitoring systems aimed at improving diabetes management.
Links to the live webcast and archived presentation will be available on the DexCom Investor Relations website.
On World Diabetes Day, Dexcom (NASDAQ: DXCM) launched a campaign to support the diabetes community through custom continuous glucose monitor (CGM) patches. Celebrities including Henry Slade, Roxy Horner, Sheku Kanneh-Mason, and Eoin Costelloe designed patches to share their personal diabetes stories. The initiative aims to promote visibility and understanding of diabetes, encouraging others to join the movement. Participants can create their designs at UK.SeeDiabetes.com, with the first 500 submissions receiving free patches. Dexcom focuses on real-time diabetes management through innovative CGM technologies.
In November, Dexcom (NASDAQ: DXCM) launches the #SeeDiabetes campaign to enhance access to diabetes care during National Diabetes Awareness Month. This initiative features celebrity advocates like Patti LaBelle and Mark Andrews, who collaborate with artists to create custom Dexcom G6 patches. The campaign aims to raise awareness of coverage challenges for diabetes technology and celebrate the resilience of those living with diabetes. The initiative aligns with World Diabetes Day, advocating for expanded access to continuous glucose monitoring technology, especially following a recent CMS proposal.
DexCom reported its Q3 2022 financial results, with revenues increasing 18% year-over-year to $769.6 million. U.S. revenue grew 17% and international revenue soared 22%. GAAP operating income reached $147.5 million (19.2% of revenue), up from $118.3 million in Q3 2021. The company updated its annual revenue guidance to $2.88 - 2.91 billion. Significant strategic moves include launching the Dexcom G7 in five countries and expanding access to CGM through NHS inclusion.
DexCom, Inc. (NASDAQ: DXCM) has launched its inaugural program, Dexcom U, aimed at supporting college athletes with diabetes. The program features 14 athletes from 11 sports, promoting representation and inspiration for aspiring athletes facing similar challenges. A survey reveals that 43% of adults with Type 1 diabetes considered quitting sports due to their condition. Dexcom U, in collaboration with ESPN's Adam Schefter, provides mentorship and a platform for these athletes. The program emphasizes the role of continuous glucose monitoring in empowering athletes to manage their diabetes effectively.
Dexcom announces the launch of its G7 Continuous Glucose Monitoring (CGM) System in the UK, Ireland, Germany, Austria, and Hong Kong, aimed at people aged two and older. The G7 features the fastest sensor warmup in the market, with no finger sticks required, and builds on the accuracy of Dexcom's previous products. A global streaming launch event showcased the device, with plans for launches in New Zealand and South Africa soon. With improved design and integration into automated insulin delivery systems, Dexcom G7 marks a significant advancement in diabetes management.
DexCom, Inc. (NASDAQ:DXCM) will release its third quarter 2022 financial results on October 27, 2022, after market close.
A conference call is scheduled for 4:30 p.m. (Eastern Time) on the same day to review performance, with a webcast available on their investor relations website.
Investors can call in at (866) 374-5140 (US/Canada) or (404) 400-0571 (International) using confirmation number 56107665#.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
